Natera Inc (NAS:NTRA)
$ 127.21 -2.46 (-1.9%) Market Cap: 15.73 Bil Enterprise Value: 15.59 Bil PE Ratio: 0 PB Ratio: 18.76 GF Score: 72/100

Natera Inc at Cowen Health Care Conference (Virtual) Transcript

Mar 08, 2022 / 07:50PM GMT
Release Date Price: $54.75 (+4.23%)
Max Masucci
Cowen and Company, LLC, Research Division - Senior Analyst

Good afternoon. I'm Max Masucci, one of the life science and diagnostic tools analyst here at Cowen. It's my pleasure to welcome Natera to our conference this year. Natera is a company that I've been following since 2017, a market leader in NIPT, a major participant in MRD monitoring and also blood-based organ transplant rejection testing. So we're joined by Natera's CEO, Steve Chapman; and CFO, Mike Brophy. Great to see you guys.

Steve Leonard Chapman
Natera, Inc. - CEO, President & Director

Thanks, Max.

Questions & Answers

Max Masucci
Cowen and Company, LLC, Research Division - Senior Analyst

Awesome. So let's jump in on Signatera first. You provided a snapshot of the cumulative Signatera plus Altera volumes at the time of the Q4 call. There's a [4x-ing] over the past year from [18,000 to north of 76,000]. So I guess to start, is there any way for us to think about what percentage of that [76,000] number includes tests that are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot